Shuo Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuo Yuan has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Min Liu
Zhengzhou University
17 shared publications - Bin Yu
College of Chemistry, Pingyuan Laboratory, Zhengzhou University, Zhengzhou, 450001, China
11 shared publications Yi-Ru Bai
School of Chemistry and Chemical Engineering, Henan University of Technology
9 shared publications- Jian Song
Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
7 shared publications - Sai-Yang Zhang
Zhengzhou University
7 shared publications - Zhangxu He
Pharmacy College, Henan University of Chinese Medicine, 450046 Zhengzhou, PR China
4 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2704735
A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect
In 2025, the U.S. Food and Drug Administration (FDA) approved 46 drug marketing applications, encompassing 15 biological products and 31 new molecular entities1–3. These drugs were primarily concen...
- 20 July 2026
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 41 (1) , 2704735
Open AccessA comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect
In 2025, the U.S. Food and Drug Administration (FDA) approved 46 drug marketing applications, encompassing 15 biological products and 31 new molecular entities1–3. These drugs were primarily concen...
- 6 August 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108847
The LSD1/HDAC dual-target inhibitor for cancer therapy: Challenge and opportunity
- 6 August 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108847
The LSD1/HDAC dual-target inhibitor for cancer therapy: Challenge and opportunity
- 17 July 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117980
The prospects and challenges of small molecule drugs in the treatment of Duchenne muscular dystrophy
- 17 July 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117980
The prospects and challenges of small molecule drugs in the treatment of Duchenne muscular dystrophy
- 20 January 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 156, 108189
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
- 20 January 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 156, 108189
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
- 31 October 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (22) , 16485-16492
Functional Hexafluoroisopropyl Group Used in the Construction of Biologically Important Pyrimidine Derivatives
A series of versatile 4-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)pyridine intermediates have been developed to efficiently produce biaryls, amines, ethers, and thioethers. These hydrolysis-stable ether intermediates exhibit reactivity toward electron-donating groups and nucleophiles in cross-coupling and nucleophilic substitution reactions while surpassing the stability of corresponding aryl halides. In comparison to conventional coupling methods, this protocol offers an alternative pathway for accessing natural product and drug-like compounds without the need for metal catalysts. With assistance of this approach, we successfully obtained a potent P-glycoprotein inhibitor 4k (YS-370), a potent epidermal growth factor receptor inhibitor 4l (YS-363), and a promising lysine-specific demethylase 1 inhibitor 5g.
- 31 October 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (22) , 16485-16492
Functional Hexafluoroisopropyl Group Used in the Construction of Biologically Important Pyrimidine Derivatives
A series of versatile 4-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)pyridine intermediates have been developed to efficiently produce biaryls, amines, ethers, and thioethers. These hydrolysis-stable ether intermediates exhibit reactivity toward electron-donating groups and nucleophiles in cross-coupling and nucleophilic substitution reactions while surpassing the stability of corresponding aryl halides. In comparison to conventional coupling methods, this protocol offers an alternative pathway for accessing natural product and drug-like compounds without the need for metal catalysts. With assistance of this approach, we successfully obtained a potent P-glycoprotein inhibitor 4k (YS-370), a potent epidermal growth factor receptor inhibitor 4l (YS-363), and a promising lysine-specific demethylase 1 inhibitor 5g.
- 10 September 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (6) , e22260
The mechanism of action and chemical synthesis of FDA newly approved drug molecules
In 2023, the U.S. Food and Drug Administration has approved 29 small molecule drugs. These newly approved small molecule drugs possess the distinct scaffolds, thereby exhibiting diverse mechanisms of action and binding modalities. Moreover, the marketed drugs have always been an important source of new drug development and creative inspiration, thereby fostering analogous endeavors in drug discovery that potentially extend to the diverse clinical indications. Therefore, conducting a comprehensive evaluation of drug approval experience and associated information will facilitate the expedited identification of highly potent drug molecules. In this review, we comprehensively summarized the relevant information regarding the clinical applications, mechanisms of action and chemical synthesis of 29 small molecule drugs, with the aim of providing a promising structural basis and design inspiration for pharmaceutical chemists.
- 10 September 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (6) , e22260
The mechanism of action and chemical synthesis of FDA newly approved drug molecules
In 2023, the U.S. Food and Drug Administration has approved 29 small molecule drugs. These newly approved small molecule drugs possess the distinct scaffolds, thereby exhibiting diverse mechanisms of action and binding modalities. Moreover, the marketed drugs have always been an important source of new drug development and creative inspiration, thereby fostering analogous endeavors in drug discovery that potentially extend to the diverse clinical indications. Therefore, conducting a comprehensive evaluation of drug approval experience and associated information will facilitate the expedited identification of highly potent drug molecules. In this review, we comprehensively summarized the relevant information regarding the clinical applications, mechanisms of action and chemical synthesis of 29 small molecule drugs, with the aim of providing a promising structural basis and design inspiration for pharmaceutical chemists.
- 10 August 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 277, 116759
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
- 10 August 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 277, 116759
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
- 22 July 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 276, 116706
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
- 22 July 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 276, 116706
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
- 15 July 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 151, 107652
Targeting DNA methyltransferases for cancer therapy
- 15 July 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 151, 107652
Targeting DNA methyltransferases for cancer therapy
- 3 February 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 144, 107171
Recent advances of Pin1 inhibitors as potential anticancer agents
- 3 February 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 144, 107171
Recent advances of Pin1 inhibitors as potential anticancer agents